Fate Therapeutics has treated the first participant in RECLAIM-LN, a Phase 2 study evaluating its off-the-shelf CD19-directed CAR T-cell candidate FT819 in people with refractory moderate-to-severe lupus nephritis.
The company disclosed the trial initiation on August 14, 2026, saying the first participant received FT819 in an outpatient setting and was discharged on the same day. Several additional patients were undergoing screening at activated sites, while the United Kingdom Medicines and Healthcare products Regulatory Agency had authorized the study at British centres.
RECLAIM-LN is expected to enrol approximately 53 participants with Class III or Class IV lupus nephritis, with or without accompanying Class V disease, after failure of at least two systemic immunosuppressive treatments. Each participant will receive bendamustine conditioning followed by one intravenous infusion containing 900 million FT819 cells.
The primary endpoint is complete renal response at Week 26. Fate Therapeutics expects to complete enrolment within approximately 15 to 18 months, placing the anticipated end of enrolment in the first half of 2028.
The clinical milestone carries significance beyond another participant receiving an experimental cell therapy. FT819 is produced from an engineered induced pluripotent stem cell master bank, allowing batches to be manufactured in advance, stored in inventory and distributed when a patient is ready. That model attempts to remove the individualized manufacturing period associated with conventional autologous CAR T-cell treatment.
Fate Therapeutics describes RECLAIM-LN as potentially registrational, reflecting its discussions with the United States Food and Drug Administration under FT819’s Regenerative Medicine Advanced Therapy designation. The wording does not mean the study is already accepted as sufficient for approval. RECLAIM-LN remains a small, open-label, single-arm trial whose ability to support a marketing application will depend on the response rate, durability, safety, manufacturing consistency and the regulator’s eventual assessment of the complete evidence package.
What will the RECLAIM-LN Phase 2 trial examine?
RECLAIM-LN is enrolling participants aged 12 to 70 with biopsy-confirmed proliferative Class III or Class IV lupus nephritis. People with an additional Class V component can also participate, provided they have active disease and investigators believe that meaningful renal improvement remains possible.
Eligible participants must show systemic lupus erythematosus activity and kidney involvement, including a urine protein-to-creatinine ratio of at least one gram per gram. They must also have failed at least two systemic immunosuppressive therapies used for lupus nephritis, placing the study in a more treatment-resistant population than many pivotal trials of approved medicines.
People receiving dialysis shortly before treatment are excluded, as are those with irreversible organ damage that investigators believe is unlikely to benefit from CD19-directed CAR T-cell therapy. The study is therefore targeting patients with serious and difficult disease, but not kidneys that have already progressed beyond a realistic opportunity for recovery.
After a screening period of up to 28 days, participants receive bendamustine followed by a single FT819 infusion. Efficacy and safety assessments continue through 24 months, after which participants enter long-term monitoring for as long as 15 years.
Complete renal response at Week 26 is the primary measure, while secondary assessments include complete renal response at later visits, partial and overall renal responses, lupus low disease activity state, remission, quality of life and patient-reported outcomes. Investigators will also follow established measures such as the Systemic Lupus Erythematosus Disease Activity Index 2000, the British Isles Lupus Assessment Group score and Physician Global Assessment.
How is FT819 designed to reset the lupus immune system?
Lupus is driven partly by abnormal B cells that produce autoantibodies, present antigens and help maintain inflammatory immune activity. In lupus nephritis, that activity damages the kidney’s filtering structures, allowing protein to leak into urine and potentially causing progressive loss of renal function.
FT819 consists of engineered T cells carrying a chimeric antigen receptor that recognizes CD19, a protein expressed across much of the B-cell lineage. When an FT819 cell encounters a CD19-positive cell, the receptor activates the engineered T cell and directs it to destroy the target.
The therapeutic objective is deeper than temporarily reducing circulating B-cell numbers. CAR T cells may enter tissues and remove disease-driving B-cell populations that survive conventional antibody therapy. New B cells can subsequently return from earlier precursor populations, potentially producing a less autoreactive immune repertoire.
This process is often described as an immune reset, although the term should be used cautiously. No universally accepted clinical or molecular definition establishes when an autoimmune immune system has genuinely been reset. A patient can show B-cell depletion and clinical improvement without achieving permanent drug-free remission.
FT819 also does not directly eliminate every antibody-producing cell. Mature long-lived plasma cells can lose CD19 expression, potentially allowing some autoantibody production to persist. The durability of response may consequently differ according to the antibodies, tissues and immune-cell populations driving an individual patient’s disease.
Why could an off-the-shelf CAR T-cell product change access?
Most approved CAR T-cell treatments use autologous manufacturing. A treatment centre collects T cells from the patient, sends them for engineering and expansion, waits for the personalized product to be released and then administers the cells after conditioning chemotherapy.
That process has transformed the treatment of several blood cancers, but it is expensive, operationally demanding and vulnerable to manufacturing delays. A patient with rapidly worsening kidney disease may not be an ideal candidate for a prolonged vein-to-vein manufacturing interval.
FT819 begins with a clonally selected induced pluripotent stem cell line rather than manufacturing a separate product from every participant. Fate Therapeutics can repeatedly use that renewable starting source to produce larger, more uniform batches intended for multiple patients.
The cells contain a CD19-targeted 1XX CAR inserted into the T-cell receptor alpha constant locus. Their endogenous T-cell receptor has been eliminated to reduce the possibility that donor-derived cells will attack the recipient’s tissues and cause graft-versus-host disease.
This manufacturing strategy could make treatment available on demand, improve batch consistency and simplify scheduling. Fate Therapeutics said its first pivotal drug-product batch had been manufactured and released, with inventory placed at distribution depots for shipment to clinical sites.
Off-the-shelf availability does not eliminate every biological difficulty. A recipient’s immune system can recognize allogeneic cells as foreign and remove them, potentially shortening FT819 expansion and persistence. The central question is whether temporary expansion is sufficient to achieve the depth of B-cell depletion required for durable autoimmune control.
How convincing are the existing FT819 Phase 1 results?
Fate Therapeutics had treated 21 people with systemic lupus erythematosus in its Phase 1 programme by the May 14, 2026 data cutoff. Sixteen received FT819 after less-intensive conditioning with either cyclophosphamide or bendamustine rather than the combined fludarabine and cyclophosphamide regimen commonly used in CAR T-cell studies.
These 16 participants had a mean age of 33.8 years, 87.5% were female and they had failed a median of seven previous therapies. The population therefore represented heavily treated disease, although the Phase 1 group was not identical to the biopsy-defined lupus nephritis population being enrolled in RECLAIM-LN.
No participant in this group experienced a dose-limiting toxicity, Grade 3 or higher cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, graft-versus-host disease or death, according to the company’s presentation. Four participants, representing 25%, developed Grade 1 or Grade 2 cytokine release syndrome.
The absence of severe cytokine release syndrome and neurotoxicity is encouraging, particularly for an outpatient strategy. However, six of the 16 participants experienced a Grade 3 or higher adverse event. Grade 3 or higher infections occurred in three participants, while three developed Grade 3 or higher cytopenia.
Disease-activity measures moved in a favourable direction, including systemic lupus scores, urine protein-to-creatinine ratios, physician assessments and fatigue. Among 10 evaluable participants who entered treatment using glucocorticoids, seven reduced their dose to five milligrams per day or less, including five who discontinued steroids.
B-cell receptor sequencing in five evaluated participants showed reductions of between 74% and 96% in the 50 most expanded B-cell clones detected at baseline. Those dominant clones had not reappeared during analysed follow-up extending to 12 months, while tested vaccine antibody titres were maintained.
These findings support the mechanism and justify later testing, but they do not establish a complete renal response rate for the RECLAIM-LN population. The Phase 1 programme was small, uncontrolled and included different conditioning approaches, cell doses and manifestations of systemic lupus erythematosus.
Fate Therapeutics observed deeper B-cell depletion and stronger disease improvement with bendamustine than with cyclophosphamide. That comparison was not generated through a sufficiently large randomized study, meaning differences in participants, disease severity, cell exposure or follow-up could have contributed.
Can complete renal response at Week 26 support an approval application?
Complete renal response combines several clinically important measurements, generally including substantial control of proteinuria, preservation of kidney filtration, restricted glucocorticoid use and avoidance of rescue treatment. Achieving this state is associated with better long-term kidney outcomes than leaving active inflammation uncontrolled.
RECLAIM-LN measures its primary endpoint only 26 weeks after FT819 treatment. That timeline can reveal whether the cell therapy produces a rapid renal response, but it is too short to establish that the benefit prevents kidney failure or remains durable for several years.
The single-arm structure presents a further challenge. Every participant receives bendamustine and FT819, leaving no contemporaneous group receiving standard treatment alone. Investigators and regulators must therefore interpret the result against prespecified expectations, historical data, each participant’s previous treatment failure and the pattern of change after infusion.
Lupus nephritis can fluctuate, while proteinuria may improve at a different rate from underlying immune activity. Changes in glucocorticoids, background immunosuppression, blood-pressure control and supportive kidney treatment can also affect renal measurements.
A large response rate accompanied by steroid reduction, preserved kidney function and sustained remission could create a persuasive accelerated-development argument in patients who have exhausted available options. A modest response or one that weakens after B cells return would make a controlled confirmatory study more likely.
Potentially registrational therefore describes an intended regulatory path rather than an agreed outcome. Regenerative Medicine Advanced Therapy designation enables closer communication with the Food and Drug Administration, but it does not lower the statutory requirement to demonstrate safety and effectiveness.
How does FT819 compare with approved lupus nephritis treatments?
The lupus nephritis treatment landscape has changed substantially since prolonged glucocorticoids, mycophenolate mofetil and cyclophosphamide dominated care.
Benlysta, developed by GSK, inhibits B-lymphocyte stimulator and is used with standard therapy. In the 448-participant BLISS-LN trial, 43% of participants receiving Benlysta plus standard treatment achieved the primary renal response at Week 104, compared with 32% receiving placebo plus standard therapy. Complete renal response occurred in 30% and 20%, respectively.
Lupkynis, developed by Aurinia Pharmaceuticals, is an oral calcineurin inhibitor used with background immunosuppression. In the 357-participant AURORA 1 trial, complete renal response at Week 52 occurred in 41% of the Lupkynis group and 23% of the control group.
Gazyva, developed by Genentech, became the first anti-CD20 monoclonal antibody approved in the United States for adults with active lupus nephritis in October 2025. In the randomized REGENCY trial, 46.4% of participants receiving Gazyva plus standard therapy achieved complete renal response at Week 76, compared with 33.1% receiving standard therapy alone.
Those figures should not be directly compared with a future RECLAIM-LN response rate. The populations, background therapies, definitions and assessment times differ, while RECLAIM-LN specifically requires failure of at least two immunosuppressive treatments.
The comparison nevertheless shows what FT819 must eventually improve. Approved medicines already increase renal response when added to standard care, but they generally require repeated or continuing administration. FT819 is pursuing a one-infusion strategy intended to produce deeper B-cell depletion and prolonged disease control.
A meaningful advantage would include sustained remission after reducing or discontinuing chronic immunosuppression. A temporary improvement followed by renewed treatment would weaken the economic and clinical case for accepting the risks of conditioning chemotherapy and genetically modified cells.
What safety risks must RECLAIM-LN clarify?
The favourable early cytokine release syndrome and neurotoxicity profile supports outpatient investigation, but 16 participants are insufficient to characterize uncommon or delayed complications.
CAR T-cell therapy can cause cytokine release syndrome, neurological toxicity, prolonged cytopenias and serious infections. Allogeneic products also create concerns about graft-versus-host disease and immune rejection, even when engineering is intended to reduce those risks.
FT819’s T-cell receptor knockout is designed to limit graft-versus-host disease. The absence of reported cases in the Phase 1 lupus group is encouraging, but RECLAIM-LN must confirm that finding across more participants, treatment centres and production lots.
Bendamustine is described as less intensive than the frequently used fludarabine and cyclophosphamide combination, but it remains chemotherapy. It can suppress lymphocytes and bone marrow function, increasing vulnerability to infection and cytopenia during the period surrounding FT819 infusion.
That distinction matters in a predominantly young lupus population and becomes especially important because RECLAIM-LN permits participants as young as 12. Investigators must consider acute tolerability, reproductive implications, infection prevention and the long-term consequences of exposing adolescents to conditioning and genetically modified cells.
Deep B-cell depletion may also reduce immunoglobulin levels or weaken responses to infection. Fate Therapeutics reported no hypogammaglobulinemia in the 16-person Phase 1 group and preserved vaccine titres in tested participants, but larger numbers and longer observation are required.
The study’s 15-year follow-up reflects the need to monitor survival, secondary malignancies and other delayed effects associated with genetically modified cell therapies. A same-day discharge policy changes the location of initial observation, not the need for long-term surveillance.
Does same-day discharge make FT819 a community treatment?
Treating the first RECLAIM-LN participant as an outpatient is an operational achievement, particularly when most public familiarity with CAR T-cell therapy comes from oncology programmes involving prolonged observation at specialist centres.
Fate Therapeutics had already administered FT819 in outpatient and community-hospital settings during Phase 1. A ready-to-ship product removes the need for on-site cell collection and coordination with a personalized manufacturing slot.
Same-day discharge does not mean FT819 can immediately be administered in an ordinary rheumatology clinic. Centres still require expertise in conditioning chemotherapy, cell handling, infection prevention, recognition of cytokine release syndrome and emergency escalation.
Patients may also need to remain within travelling distance of the treatment centre during the highest-risk period. Laboratory monitoring, caregiver support and rapid access to hospital care remain part of the real treatment burden even when an overnight admission is avoided.
Broad adoption will depend on whether community hospitals can build this capability without reproducing the expense and complexity of oncology CAR T centres. Reimbursement must account for the cell product, bendamustine, monitoring, specialist staff and management of complications.
The outpatient model will become persuasive if RECLAIM-LN shows consistently low rates of severe acute toxicity across several centres. One successful same-day discharge demonstrates feasibility for that individual patient, not universal suitability.
How does FT819 compare with other autoimmune CAR T-cell programmes?
Fate Therapeutics is not alone in attempting to move CD19-directed CAR T-cell therapy into autoimmune disease.
Kyverna Therapeutics is developing mivocabtagene autoleucel, previously called KYV-101, in Phase 1/2 lupus nephritis studies. Cabaletta Bio is evaluating resecabtagene autoleucel in its RESET-SLE Phase 1/2 programme, while Novartis is conducting a larger Phase 2 study of rapcabtagene autoleucel in refractory systemic lupus erythematosus and lupus nephritis.
These programmes use autologous cells collected from the patient. Their potential advantage is better compatibility with the recipient’s immune system, which may support cell expansion and reduce rejection. Their disadvantage is the individualized manufacturing process that FT819 is designed to avoid.
The Novartis study is expected to enrol 179 participants and includes a randomized comparison against standard care for its lupus nephritis assessment. If successful, that design could provide more conventionally persuasive comparative evidence than the 53-person single-arm RECLAIM-LN study.
FT819’s differentiation therefore rests on accessibility, consistency and outpatient delivery rather than being the only CD19-directed CAR T-cell therapy in lupus. Fate Therapeutics must show that a readily available allogeneic product can achieve sufficient expansion and durable disease control without the need to manufacture cells from each patient.
Can Fate Therapeutics keep manufacturing ready for an accelerated pathway?
Cell-therapy development can move faster clinically than the manufacturing programme needed to support commercial approval. Small process changes can alter cell composition, potency, expansion or persistence, creating comparability questions between early and later batches.
The Food and Drug Administration selected FT819 for its Chemistry, Manufacturing and Controls Development and Readiness Pilot. The programme provides additional communication intended to keep manufacturing development aligned with accelerated clinical timelines.
Fate Therapeutics said it had discussed its potency strategy and other manufacturing-readiness elements with the regulator. Such interaction can identify problems earlier, but it does not guarantee that the eventual potency assay, commercial process or comparability package will be accepted in a marketing application.
A clonal induced pluripotent stem cell bank offers an attractive answer to product consistency. The same engineered starting line can generate many doses, potentially reducing the variability associated with patient-derived cells.
The commercial claims still require evidence. Fate Therapeutics has not established a final treatment price, real-world cost per dose, commercial manufacturing yield or the number of patients that can be supplied from one production campaign.
The company reported $153.8 million in cash, cash equivalents and investments at the end of June and expects its operating runway to extend into 2028. That timing reaches the anticipated RECLAIM-LN enrolment period, but longer follow-up, manufacturing validation and preparations for a possible marketing application could require additional capital.
Could FT819 make CAR T a practical lupus nephritis treatment?
RECLAIM-LN moves FT819 from an exploratory autoimmune basket study into a defined renal trial with a specific dose, conditioning regimen, population and primary endpoint.
The programme has several credible strengths. FT819 can be manufactured in advance, the initial pivotal batch has been released, the first participant received treatment without overnight hospitalization and the Phase 1 experience has not produced severe cytokine release syndrome, neurotoxicity or graft-versus-host disease.
The early evidence also points toward biological activity. FT819 depleted B cells, reduced dominant B-cell clones, improved several disease measures and allowed some participants to reduce or discontinue glucocorticoids.
The limitations remain substantial. The evidence comes from a small uncontrolled Phase 1 population, formal complete renal response data for the RECLAIM-LN population are unavailable and Grade 3 or higher infections and cytopenias occurred in almost one-fifth of the less-intensive-conditioning group.
RECLAIM-LN must now show that one 900 million-cell dose produces a complete renal response rate clearly exceeding what would be expected in patients who have failed multiple therapies. It must also demonstrate that responses persist beyond Week 26, kidney function remains stable and patients can reduce chronic immunosuppression without allowing lupus activity to return.
If those results emerge with manageable toxicity, FT819 could challenge the assumption that CAR T-cell therapy must be individually manufactured and confined to highly specialized inpatient programmes. Its off-the-shelf design may become especially valuable when patients need treatment before kidney damage becomes irreversible.
The trial initiation does not yet establish FT819 as a registrational product or an outpatient standard. It does, however, create one of the clearest tests of whether industrially manufactured CAR T cells can move from oncology into a chronic autoimmune disease and deliver something conventional B-cell therapy rarely promises: a practical, one-time attempt at durable immune control.
